 | • レポートコード：MRC-IM30193 • 出版社/出版日：IMARC / 2022年10月 • レポート形態：英文、PDF、141ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥359,856 (USD2,499) | ▷ お問い合わせ |
| Enterprisewide | ￥647,856 (USD4,499) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| IMARC社の調査レポートによると、世界の院内感染治療市場規模は2021年に112億ドルに達しました。今後、2027年には151億ドルになり、2022年から2022年の間に年平均4.97％成長すると予測しています。本調査レポートでは、院内感染治療の世界市場について調査・分析を行い、序論、調査範囲・手法、エグゼクティブサマリー、イントロダクション、薬物種類別（抗菌薬、抗真菌薬、抗ウイルス薬、その他）分析、疾患別（血流感染症、尿路感染症、手術部位感染、肺炎、その他）分析、地域別（北米、アジア、欧州、中南米、中東・アフリカ）分析、SWOT分析（強み・弱み・機会・脅威）、バリューチェーン分析、ファイブフォース分析、価格分析、競争状況などを掲載しています。なお、企業情報には、Allergan Plc (AbbVie Inc.), AstraZeneca Plc, Bayer Aktiengesellschaft, Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc, Pfizer Inc. and Sanofi S.A.などが含まれています。 ・序論 ・調査範囲・手法 ・エグゼクティブサマリー ・イントロダクション ・世界の院内感染治療市場規模：薬物種類別 - 抗菌薬の市場規模 - 抗真菌薬の市場規模 - 抗ウイルス薬の市場規模 - その他薬物の市場規模 ・世界の院内感染治療市場規模：疾患別 - 血流感染症における市場規模 - 尿路感染症における市場規模 - 手術部位感染における市場規模 - 肺炎における市場規模 - その他疾患における市場規模 ・世界の院内感染治療市場規模：地域別 - 北米の院内感染治療市場規模 - アジアの院内感染治療市場規模 - 欧州の院内感染治療市場規模 - 中南米の院内感染治療市場規模 - 中東・アフリカの院内感染治療市場規模 ・SWOT分析（強み・弱み・機会・脅威） ・バリューチェーン分析 ・ファイブフォース分析 ・価格分析 ・競争状況 |
The global hospital infection therapeutics market size reached US$ 11.2 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 15.1 Billion by 2027, exhibiting a growth rate (CAGR) of 4.97% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Hospital infection therapeutics refers to various pharmaceutical drugs used for the treatment of nosocomial infections. These infections can be acquired at hospitals, nursing homes, rehabilitation facilities and other clinical settings and are usually treated by antiviral, antibacterial and antifungal medicines. The antibacterial therapeutics consist of cell wall synthesis and protein synthesis inhibitors, such as vancomycin, carbapenems, cephalosporins, linezolid, aminoglycosides and tigecycline. The antifungal therapeutics include caspofungin and Amphotericin B. These drugs aid in preventing the instances of hospital-acquired pneumonia, urinary tract infections (UTIs), gastrointestinal disorders, bloodstream infections and surgical site infections.
The increasing prevalence of hospital-acquired diseases (HAD) is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. Resulting from the deterioration of hygiene facilities in hospitals and other healthcare institutions, there has been a significant increase in the occurrence of hospital-acquired pneumonia and other infections, which is contributing to the increasing demand for hospital infection therapeutics. Additionally, various product innovations, such as the development of advanced microbial wound care drugs, coverings and vaccines, are acting as other growth-inducing factors. Product manufacturers are developing antimicrobial drugs and pipeline drug molecules that are effective against multi-drug resistant infections and can be used for the treatment of infections with specific symptoms. Other factors, including extensive research and development (R&D) activities, along with improvements in the healthcare infrastructure, are expected to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global hospital infection therapeutics market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on drug type and indication.
Breakup by Drug Type:
Anti-bacterial Drugs
Anti-fungal Drugs
Anti-viral Drugs
Others
Breakup by Indication:
Blood Stream Infections
Urinary Tract Infections
Surgical Site Infections
Pneumonia
Others
Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Allergan Plc (AbbVie Inc.), AstraZeneca Plc, Bayer Aktiengesellschaft, Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc, Pfizer Inc. and Sanofi S.A.
Key Questions Answered in This Report:
How has the global hospital infection therapeutics market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global hospital infection therapeutics market?
What are the key regional markets?
What is the breakup of the market based on the drug type?
What is the breakup of the market based on the indication?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global hospital infection therapeutics market and who are the key players?
What is the degree of competition in the industry?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Hospital Infection Therapeutics Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug Type
6.1 Anti-bacterial Drugs
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Anti-fungal Drugs
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Anti-viral Drugs
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Others
6.4.1 Market Trends
6.4.2 Market Forecast
7 Market Breakup by Indication
7.1 Blood Stream Infections
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Urinary Tract Infections
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Surgical Site Infections
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Pneumonia
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Others
7.5.1 Market Trends
7.5.2 Market Forecast
8 Market Breakup by Region
8.1 North America
8.1.1 United States
8.1.1.1 Market Trends
8.1.1.2 Market Forecast
8.1.2 Canada
8.1.2.1 Market Trends
8.1.2.2 Market Forecast
8.2 Asia Pacific
8.2.1 China
8.2.1.1 Market Trends
8.2.1.2 Market Forecast
8.2.2 Japan
8.2.2.1 Market Trends
8.2.2.2 Market Forecast
8.2.3 India
8.2.3.1 Market Trends
8.2.3.2 Market Forecast
8.2.4 South Korea
8.2.4.1 Market Trends
8.2.4.2 Market Forecast
8.2.5 Australia
8.2.5.1 Market Trends
8.2.5.2 Market Forecast
8.2.6 Indonesia
8.2.6.1 Market Trends
8.2.6.2 Market Forecast
8.2.7 Others
8.2.7.1 Market Trends
8.2.7.2 Market Forecast
8.3 Europe
8.3.1 Germany
8.3.1.1 Market Trends
8.3.1.2 Market Forecast
8.3.2 France
8.3.2.1 Market Trends
8.3.2.2 Market Forecast
8.3.3 United Kingdom
8.3.3.1 Market Trends
8.3.3.2 Market Forecast
8.3.4 Italy
8.3.4.1 Market Trends
8.3.4.2 Market Forecast
8.3.5 Spain
8.3.5.1 Market Trends
8.3.5.2 Market Forecast
8.3.6 Russia
8.3.6.1 Market Trends
8.3.6.2 Market Forecast
8.3.7 Others
8.3.7.1 Market Trends
8.3.7.2 Market Forecast
8.4 Latin America
8.4.1 Brazil
8.4.1.1 Market Trends
8.4.1.2 Market Forecast
8.4.2 Mexico
8.4.2.1 Market Trends
8.4.2.2 Market Forecast
8.4.3 Others
8.4.3.1 Market Trends
8.4.3.2 Market Forecast
8.5 Middle East and Africa
8.5.1 Market Trends
8.5.2 Market Breakup by Country
8.5.3 Market Forecast
9 SWOT Analysis
9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 Allergan Plc (AbbVie Inc.)
13.3.1.1 Company Overview
13.3.1.2 Product Portfolio
13.3.1.3 Financials
13.3.1.4 SWOT Analysis
13.3.2 AstraZeneca Plc
13.3.2.1 Company Overview
13.3.2.2 Product Portfolio
13.3.2.3 Financials
13.3.2.4 SWOT Analysis
13.3.3 Bayer Aktiengesellschaft
13.3.3.1 Company Overview
13.3.3.2 Product Portfolio
13.3.3.3 Financials
13.3.3.4 SWOT Analysis
13.3.4 Bristol-Myers Squibb Company
13.3.4.1 Company Overview
13.3.4.2 Product Portfolio
13.3.4.3 Financials
13.3.4.4 SWOT Analysis
13.3.5 F. Hoffmann-La Roche AG (Roche Holding AG)
13.3.5.1 Company Overview
13.3.5.2 Product Portfolio
13.3.5.3 SWOT Analysis
13.3.6 Gilead Sciences Inc.
13.3.6.1 Company Overview
13.3.6.2 Product Portfolio
13.3.6.3 Financials
13.3.6.4 SWOT Analysis
13.3.7 GlaxoSmithKline Plc
13.3.7.1 Company Overview
13.3.7.2 Product Portfolio
13.3.7.3 Financials
13.3.7.4 SWOT Analysis
13.3.8 Johnson & Johnson
13.3.8.1 Company Overview
13.3.8.2 Product Portfolio
13.3.8.3 Financials
13.3.8.4 SWOT Analysis
13.3.9 Merck & Co. Inc.
13.3.9.1 Company Overview
13.3.9.2 Product Portfolio
13.3.9.3 Financials
13.3.9.4 SWOT Analysis
13.3.10 Pfizer Inc.
13.3.10.1 Company Overview
13.3.10.2 Product Portfolio
13.3.10.3 Financials
13.3.10.4 SWOT Analysis
13.3.11 Sanofi S.A.
13.3.11.1 Company Overview
13.3.11.2 Product Portfolio
13.3.11.3 Financials
13.3.11.4 SWOT Analysis
Figure 2: Global: Hospital Infection Therapeutics Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Hospital Infection Therapeutics Market: Breakup by Drug Type (in %), 2021
Figure 4: Global: Hospital Infection Therapeutics Market: Breakup by Indication (in %), 2021
Figure 5: Global: Hospital Infection Therapeutics Market: Breakup by Region (in %), 2021
Figure 6: Global: Hospital Infection Therapeutics Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 7: Global: Hospital Infection Therapeutics (Anti-bacterial Drugs) Market: Sales Value (in Million US$), 2016 & 2021
Figure 8: Global: Hospital Infection Therapeutics (Anti-bacterial Drugs) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 9: Global: Hospital Infection Therapeutics (Anti-fungal Drugs) Market: Sales Value (in Million US$), 2016 & 2021
Figure 10: Global: Hospital Infection Therapeutics (Anti-fungal Drugs) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 11: Global: Hospital Infection Therapeutics (Anti-viral Drugs) Market: Sales Value (in Million US$), 2016 & 2021
Figure 12: Global: Hospital Infection Therapeutics (Anti-viral Drugs) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 13: Global: Hospital Infection Therapeutics (Other Drug Types) Market: Sales Value (in Million US$), 2016 & 2021
Figure 14: Global: Hospital Infection Therapeutics (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 15: Global: Hospital Infection Therapeutics (Blood Stream Infections) Market: Sales Value (in Million US$), 2016 & 2021
Figure 16: Global: Hospital Infection Therapeutics (Blood Stream Infections) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 17: Global: Hospital Infection Therapeutics (Urinary Tract Infections) Market: Sales Value (in Million US$), 2016 & 2021
Figure 18: Global: Hospital Infection Therapeutics (Urinary Tract Infections) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 19: Global: Hospital Infection Therapeutics (Surgical Site Infections) Market: Sales Value (in Million US$), 2016 & 2021
Figure 20: Global: Hospital Infection Therapeutics (Surgical Site Infections) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 21: Global: Hospital Infection Therapeutics (Pneumonia) Market: Sales Value (in Million US$), 2016 & 2021
Figure 22: Global: Hospital Infection Therapeutics (Pneumonia) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 23: Global: Hospital Infection Therapeutics (Other Indications) Market: Sales Value (in Million US$), 2016 & 2021
Figure 24: Global: Hospital Infection Therapeutics (Other Indications) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 25: North America: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 26: North America: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 27: United States: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 28: United States: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 29: Canada: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 30: Canada: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 31: Asia Pacific: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 32: Asia Pacific: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 33: China: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 34: China: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 35: Japan: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 36: Japan: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 37: India: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 38: India: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 39: South Korea: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 40: South Korea: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 41: Australia: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 42: Australia: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 43: Indonesia: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 44: Indonesia: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 45: Others: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 46: Others: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 47: Europe: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 48: Europe: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 49: Germany: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 50: Germany: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 51: France: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 52: France: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 53: United Kingdom: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 54: United Kingdom: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 55: Italy: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 56: Italy: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 57: Spain: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 58: Spain: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 59: Russia: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 60: Russia: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 61: Others: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 62: Others: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 63: Latin America: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 64: Latin America: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 65: Brazil: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 66: Brazil: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 67: Mexico: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 68: Mexico: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 69: Others: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 70: Others: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 71: Middle East and Africa: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 72: Middle East and Africa: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 73: Global: Hospital Infection Therapeutics Industry: SWOT Analysis
Figure 74: Global: Hospital Infection Therapeutics Industry: Value Chain Analysis
Figure 75: Global: Hospital Infection Therapeutics Industry: Porter’s Five Forces Analysis
• 日本語訳：院内感染治療の世界市場：動向・シェア・規模・予測
• レポートコード：MRC-IM30193 ▷ お問い合わせ（見積依頼・ご注文・質問）